Search Results - "Vernaci, Grazia"

Evolution of HER2-low expression from primary to recurrent breast cancer by Miglietta, Federica, Griguolo, Gaia, Bottosso, Michele, Giarratano, Tommaso, Lo Mele, Marcello, Fassan, Matteo, Cacciatore, Matilde, Genovesi, Elisa, De Bartolo, Debora, Vernaci, Grazia, Amato, Ottavia, Conte, PierFranco, Guarneri, Valentina, Dieci, Maria Vittoria

“…About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is…”
Get full text

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy by Dieci, Maria Vittoria, Griguolo, Gaia, Bottosso, Michele, Tsvetkova, Vassilena, Giorgi, Carlo Alberto, Vernaci, Grazia, Michieletto, Silvia, Angelini, Silvia, Marchet, Alberto, Tasca, Giulia, Genovesi, Elisa, Cumerlato, Enrico, Lo Mele, Marcello, Conte, PierFranco, Guarneri, Valentina

“…Although 1% is the recommended cut-off to define estrogen receptor (ER) positivity, a 10% cut-off is often used in clinical practice for therapeutic purposes…”
Get full text

Immune characterization of breast cancer metastases: prognostic implications by Dieci, Maria Vittoria, Tsvetkova, Vassilena, Orvieto, Enrico, Piacentini, Federico, Ficarra, Guido, Griguolo, Gaia, Miglietta, Federica, Giarratano, Tommaso, Omarini, Claudia, Bonaguro, Serena, Cappellesso, Rocco, Aliberti, Camillo, Vernaci, Grazia, Giorgi, Carlo Alberto, Faggioni, Giovanni, Tasca, Giulia, Conte, Pierfranco, Guarneri, Valentina

“…Tumor-infiltrating lymphocytes (TILs) evaluated in primary breast cancer (BC) convey prognostic information. Limited data in the metastatic setting are…”
Get full text

ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis by Urso, Loredana, Vernaci, Grazia, Carlet, Jessica, Lo Mele, Marcello, Fassan, Matteo, Zulato, Elisabetta, Faggioni, Giovanni, Menichetti, Alice, Di Liso, Elisabetta, Griguolo, Gaia, Falci, Cristina, Conte, Pierfranco, Indraccolo, Stefano, Guarneri, Valentina, Dieci, Maria Vittoria

“…Endocrine therapy represents the cornerstone of treatment in hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC). The natural course…”
Get full text

Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease by Dieci, Maria Vittoria, Tsvetkova, Vassilena, Griguolo, Gaia, Miglietta, Federica, Mantiero, Mara, Tasca, Giulia, Cumerlato, Enrico, Giorgi, Carlo Alberto, Giarratano, Tommaso, Faggioni, Giovanni, Falci, Cristina, Vernaci, Grazia, Menichetti, Alice, Mioranza, Eleonora, Di Liso, Elisabetta, Frezzini, Simona, Saibene, Tania, Orvieto, Enrico, Guarneri, Valentina

“…We evaluated immunohistochemical AR expression and correlation with prognosis in a large series of homogeneously treated patients with primary TNBC. Patients…”
Get full text

HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment by Miglietta, Federica, Griguolo, Gaia, Bottosso, Michele, Giarratano, Tommaso, Lo Mele, Marcello, Fassan, Matteo, Cacciatore, Matilde, Genovesi, Elisa, De Bartolo, Debora, Vernaci, Grazia, Amato, Ottavia, Porra, Francesca, Conte, PierFranco, Guarneri, Valentina, Dieci, Maria Vittoria

“…Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described a high instability of…”
Get full text

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer by Miglietta, Federica, Griguolo, Gaia, Bottosso, Michele, Giarratano, Tommaso, Lo Mele, Marcello, Fassan, Matteo, Cacciatore, Matilde, Genovesi, Elisa, De Bartolo, Debora, Vernaci, Grazia, Amato, Ottavia, Conte, PierFranco, Guarneri, Valentina, Dieci, Maria Vittoria

Get full text

Fertility Counseling Pattern over Time in Young Patients with Breast Cancer: A Retrospective Analysis at a Large Comprehensive Cancer Center by Barbieri, Caterina, Amato, Ottavia, Cattelan, Anna Chiara, Marin, Loris, Andrisani, Alessandra, Saccardi, Carlo, Giarratano, Tommaso, Faggioni, Giovanni, Di Liso, Elisabetta, Giorgi, Carlo Alberto, Mioranza, Eleonora, Falci, Cristina, Vernaci, Grazia Maria, Tozzi, Roberto, Guarneri, Valentina, Dieci, Maria Vittoria

“…Background: One main issue to be considered in young patients diagnosed with early breast cancer (BC) is the impact of oncological treatments on fertility and…”
Get full text

Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review by Vernaci, Grazia Maria, Meroni, Muzio, Dieci, Maria Vittoria, Saibene, Tania, Montesco, Maria Cristina, Orvieto, Enrico, Cattelan, Annamaria, Ghiotto, Cristina, Miglietta, Federica, Guarneri, Valentina, Cagol, Matteo

“…Pyoderma gangrenosum is a rare skin necrotizing disease that can arise on a site of surgical trauma. Its pathogenesis has recently been related to…”
Get full text

Escalation and de-escalation in HER2 positive early breast cancer by Dieci, Maria Vittoria, Vernaci, Grazia, Guarneri, Valentina

“…PURPOSE OF REVIEWCurrent standard for HER2+ early breast cancer patients includes chemotherapy and trastuzumab for 1 year. The purpose of this article is to…”
Get full text

Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2- Breast Cancer by Bottosso, Michele, Miglietta, Federica, Vernaci, Grazia Maria, Giarratano, Tommaso, Dieci, Maria Vittoria, Guarneri, Valentina, Griguolo, Gaia

“…Adjuvant endocrine therapy (ET) represents the standard of care for almost all hormone receptor (HR)+/HER2- breast cancers, and different agents and durations…”
Get full text

Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications by Griguolo, Gaia, Bottosso, Michele, Vernaci, Grazia, Miglietta, Federica, Dieci, Maria Vittoria, Guarneri, Valentina

“…[Display omitted] •Gene-expression signatures can help spare chemotherapy in HR+/HER2− breast cancer.•Genomic assays (gene-expression profiling, GEP) can be…”
Get full text

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial by Dieci, Maria Vittoria, Guarneri, Valentina, Tosi, Anna, Bisagni, Giancarlo, Musolino, Antonino, Spazzapan, Simon, Moretti, Gabriella, Vernaci, Grazia Maria, Griguolo, Gaia, Giarratano, Tommaso, Urso, Loredana, Schiavi, Francesca, Pinato, Claudia, Magni, Giovanna, Lo Mele, Marcello, De Salvo, Gian Luca, Rosato, Antonio, Conte, Pierfranco

“…The role of immunotherapy in hormone receptor (HR)-positive, HER2-negative breast cancer is underexplored. The neoadjuvant phase II GIADA trial (NCT04659551,…”
Get full text

Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? by Miglietta, Federica, Visani, Luca, Marini, Sabrina, Griguolo, Gaia, Vernaci, Grazia Maria, Bottosso, Michele, Dieci, Maria Vittoria, Meattini, Icro, Guarneri, Valentina

“…[Display omitted] •Oligometastatic breast cancer (BC) refers to metastatic BC with limited tumor burden.•OM-BC is emerging as a clinically and biologically…”
Get full text

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy by Vernaci, Grazia, Savarino, Edoardo Vincenzo, Patuzzi, Ilaria, Facchin, Sonia, Zingone, Fabiana, Massa, Davide, Faggioni, Giovanni, Giarratano, Tommaso, Miglietta, Federica, Griguolo, Gaia, Fassan, Matteo, Lo Mele, Marcello, Gasparini, Elisa, Bisagni, Giancarlo, Guarneri, Valentina, Dieci, Maria Vittoria

“…Abstract Introduction Patients with triple-negative breast cancer (TNBC) achieving a pathological complete response (pCR) after neoadjuvant chemotherapy have a…”
Get full text

Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases by Bottosso, Michele, Griguolo, Gaia, Sinoquet, Léa, Guarascio, Maria Cristina, Aldegheri, Vittoria, Miglietta, Federica, Vernaci, Grazia, Barbieri, Caterina, Girardi, Fabio, Jacot, William, Guarneri, Valentina, Darlix, Amélie, Dieci, Maria Vittoria

“…Background Brain metastases (BM) are common among HER2+ breast cancer (BC) and prognostic stratification is crucial for optimal management. BC-GPA score and…”
Get full text

Abstract P2-12-04: Characterization of gut microbiome composition in triple negative breast cancer patients treated with neoadjuvant chemotherapy by Vernaci, Grazia Maria, Massa, Davide, Patuzzi, Ilaria, Menichetti, Alice, Giarratano, Tommaso, Griguolo, Gaia, Miglietta, Federica, Fassan, Matteo, Savarino, Edoardo, Conte, PierFranco, Guarneri, Valentina, Dieci, Maria Vittoria

“…Abstract Background: Recent evidences showed intestinal microbiota to be implicated in carcinogenesis and response to chemotherapy and immune checkpoint…”
Get full text

Association of tumor-infiltrating lymphocytes (TILs) and immune signatures with PAM50 intrinsic subtyping hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of two multicentric neoadjuvant trials by Griguolo, Gaia, Paré, Laia, Miglietta, Federica, Bottosso, Michele, Generali, Daniele Giulio, Frassoldati, Antonio, Musolino, Antonino, Spazzapan, Simon, Vernaci, Grazia, Giarratano, Tommaso, Cappellesso, Rocco, Bisagni, Giancarlo, Piacentini, Federico, Tagliafico, Enrico, Cagossi, Katia, Pinato, Claudia, Schiavi, Francesca, Prat, Aleix, Dieci, Maria Vittoria, Guarneri, Valentina

“…558 Background: HR+/HER2− BCs are generally described as immunologically cold, with low levels of TILs and PD-L1. Nevertheless, the addition of immunotherapy…”
Get full text

Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer by Miglietta, Federica, Dieci, Maria Vittoria, Tsvetkova, Vassilena, Griguolo, Gaia, Vernaci, Grazia, Menichetti, Alice, Faggioni, Giovanni, Giarratano, Tommaso, Mioranza, Eleonora, Genovesi, Elisa, Cumerlato, Enrico, Bottosso, Michele, Saibene, Tania, Michieletto, Silvia, Lo Mele, Marcello, Conte, Pierfranco, Guarneri, Valentina

“…Background The integration of residual cancer burden (RCB) and post‐treatment Ki67 as residual proliferative cancer burden (RPCB) has been proposed as a…”
Get full text

BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis by Vernaci, Grazia, Dieci, Maria Vittoria, Manfrin, Silvia, Mantiero, Mara, Falci, Cristina, Faggioni, Giovanni, Mioranza, Eleonora, Menichetti, Alice, Tasca, Giulia, Griguolo, Gaia, Miglietta, Federica, Di Liso, Elisabetta, Saibene, Tania, Michieletto, Silvia, Ghiotto, Cristina, Conte, Pierfranco, Guarneri, Valentina

“…•BMI negatively affects breast cancer survival.•Higher BMI is associated with older age, post-menopausal status and advanced stages.•Obese patients experience…”
Get full text